Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|11|3|332-337

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.11, Iss.3, 2011-03, pp. : 332-337

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Strategies for Targeting the Multidrug Resistance-1 (MDR1)/P-gp Transporter in Human Malignancies

By  

Current Cancer Drug Targets, Vol. 5, Iss. 6, 2005-09 ,pp. : 445-455

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the proteasome as a therapeutic strategy against haematological malignancies

By Orlowski Robert Z   Zeger Erik L  

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 2, 2006-02 ,pp. : 117-130

Informa Healthcare

Access to resources Recommend Favorite

Disulfiram, and Disulfiram Derivatives as Novel Potential Anticancer Drugs Targeting the Ubiquitin Proteasome System in Both Preclinical and Clinical Studies

By  

Current Cancer Drug Targets, Vol. 11, Iss. 3, 2011-03 ,pp. : 338-346

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity

By  

Current Medicinal Chemistry, Vol. 25, Iss. 4, 2018-02 ,pp. : 506-524

Bentham Science Publishers

Access to resources Recommend Favorite

Research Spotlight: Targeting drug delivery systems for circumventing multidrug resistance of cancers

By Ju Rui-Jun   Mu Li-Min   Lu Wan-Liang  

Therapeutic Delivery, Vol. 4, Iss. 6, 2013-06 ,pp. : 667-671

Future Science

Access to resources Recommend Favorite